<?xml version='1.0' encoding='utf-8'?>
<document id="25418019"><sentence text="Pharmacokinetics, pharmacodynamics and clinical efficacy of dapagliflozin for the treatment of type 2 diabetes."><entity charOffset="60-73" id="DDI-PubMed.25418019.s1.e0" text="dapagliflozin" /></sentence><sentence text="Dapagliflozin (DAPA) (Farxiga or Forxiga) is a sodium glucose cotransporter 2 (SGLT2) inhibitor approved for type 2 diabetes mellitus(T2DM) treatment"><entity charOffset="0-13" id="DDI-PubMed.25418019.s2.e0" text="Dapagliflozin" /><entity charOffset="15-19" id="DDI-PubMed.25418019.s2.e1" text="DAPA" /><entity charOffset="47-61" id="DDI-PubMed.25418019.s2.e2" text="sodium glucose" /><pair ddi="false" e1="DDI-PubMed.25418019.s2.e0" e2="DDI-PubMed.25418019.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25418019.s2.e0" e2="DDI-PubMed.25418019.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25418019.s2.e0" e2="DDI-PubMed.25418019.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25418019.s2.e1" e2="DDI-PubMed.25418019.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25418019.s2.e1" e2="DDI-PubMed.25418019.s2.e2" /></sentence><sentence text="" /><sentence text="The review focuses on the pharmacokinetics (PK), pharmacodynamics(PD) and clinical studies published on DAPA"><entity charOffset="104-117" id="DDI-PubMed.25418019.s4.e0" text="DAPA" /></sentence><sentence text=" The authors searched PubMed database for English language studies describing DAPA characteristics and use in T2DM subjects published through June 2014"><entity charOffset="78-81" id="DDI-PubMed.25418019.s5.e0" text="DAPA" /></sentence><sentence text="" /><sentence text="DAPA exhibits favorable PK and PD properties and is effective in reducing glycemic levels"><entity charOffset="0-3" id="DDI-PubMed.25418019.s7.e0" text="DAPA" /></sentence><sentence text=" In addition, DAPA shows beneficial/neutral effects on other risk factors contributing to T2DM metabolic control"><entity charOffset="14-17" id="DDI-PubMed.25418019.s8.e0" text="DAPA" /></sentence><sentence text=" Increased risk of genital and urinary infections and episodes of volume depletion represent the major concerns for its use" /><sentence text=" FDA requires additional data to assess imbalances in bladder cancer and drug cardiovascular safety" /><sentence text=" The mechanism of action and the very low risk of drug-drug interaction make it an ideal drug for rapidly reducing glucotoxicity and restoring clinical response to other antidiabetic drugs" /><sentence text="" /></document>